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The way forward for TB vaccines 
 
Tuberculosis (TB) is now the largest single-pathogen cause of global adult mortality 1; more 
than 10 million incident cases of disease occur worldwide every year. In 2018, global TB 
prevention, diagnosis and treatment efforts were estimated to cost US$10.4 billion 2. With 
such a high global burden, and a current average annual incidence rate decline of only 
1.8%, new efficacious vaccines are urgently needed to accelerate progress towards the 
World Health Organization ‘End TB’ and elimination goals 1. 
  
The year 2018 was particularly uplifting for the field of TB vaccine development, as 
unprecedented results were reported from two proof of concept efficacy trials. Van Der 
Meeren and colleagues reported that the GSK subunit vaccine M72/AS01E, consisting of Mtb 
antigens and monophosphoryl lipid A and QS21 formulated in liposomes as adjuvant, 
prevented pulmonary TB disease in adults already-infected with Mycobacterium tuberculosis 
(Mtb) 3. The vaccine efficacy in this phase IIB trial was 54% (95% CI, 3-78). Nemes and 
colleagues reported that bacille Calmette–Guérin (BCG) revaccination of previously-
uninfected adolescents protected against Mtb infection, as defined by sustained conversion 
of the Quantiferon Gold In Tube test 4. The BCG revaccination vaccine efficacy was 45% 
(95% CI, 6-68) for this secondary study endpoint. 
 
These results could translate into a significant breakthrough for TB prevention if the 
protective effects against pulmonary disease could be confirmed (for M72/AS01E) or 
demonstrated (for BCG revaccination), and shown to be generalisable. For example, in 
India, preliminary mathematical modelling has suggested that a vaccine rolled out in 2025 
with characteristics similar to those demonstrated for M72/AS01E in the phase IIB trial, and 
with a duration of efficacy of 10 years, could, as a single intervention, reduce TB incidence in 
2050 by around 40% 5. 
  
For M72/AS01E, a larger confirmatory trial, powered to improve the accuracy of efficacy 
estimates, is now needed. This trial could also explore whether age and gender affect 
protection, as suggested in secondary analyses based on a limited number of cases 3. 
Further investigations should also include examining protection in Mtb-uninfected persons 
and in high risk groups such as HIV-infected persons, and on what the duration of vaccine 
protection could be. Involving multiple geographies would be required to support 
generalisability of the findings. Investments are not only needed for the next phase of clinical 
trials, but also to ensure sustainable and affordable supply of vaccine antigens and adjuvant. 
Preparatory work on licensure and policy pathways, equitable access, and delivery should 
be initiated early to allow rapid implementation, should phase III trial results be positive. 
  
The observation that adolescent BCG revaccination may prevent sustained Mtb infection 
also requires further investigation, for multiple reasons. The estimate of effect should be 
generated in trials with more precision, as the confidence intervals were wide 4. Then, 
whether prevention of Mtb infection translates into protection against TB disease should be 
characterized, as ultimately a policy recommendation for adolescent BCG revaccination by 
the WHO would likely require demonstration of prevention of pulmonary TB disease 6.  At 
this stage, evidence appraisal would need to take into account previous studies of BCG 
revaccination showing little, or no, impact on prevention of tuberculosis disease 7–10. Even if 
confirmed, obstacles to delivery of BCG would include the current contra-indication of the 
vaccine in HIV-infected persons.  
 
Multiple other TB vaccine candidates are currently in clinical development, mostly for 
prevention of adolescent/adult TB disease. Some candidates are being developed for BCG 
replacement in neonates, although this strategy is likely to have lower population level 
impact before 2050, than efficacious vaccination at older ages 11. Three vaccines have 
entered, or are about to enter, efficacy trials for prevention of adult TB disease: two 
inactivated nontuberculous mycobacterial vaccines, Vaccae (Anhui Zhifei Longcom, contains 
Mycobacterium vaccae) and Immunovac (Cadila Pharmaceuticals, contains Mycobacterium 
w, aka M. indices pranii), and a recombinant BCG vaccine (VPM-1002, Serum Institute India, 
contains a listeriolysin insertion and urease deletion). Three vaccines will be tested for ability 
to prevent recurrence of adult TB disease after successful cure: VPM-1002 and 2 novel 
subunit vaccines, ID-93/GLA-SE (IDRI, contains two Mtb antigens and glucopyranosyl lipid 
formulated in a stable emulsion as adjuvant) and H56/IC31 (States Serum Institut, contains 
three Mtb antigens and an 11-mer antibacterial peptide and a synthetic oligodeoxynucleotide 
as adjuvant). Vaccines that are currently being, or will soon be, tested for ability to prevent 
Mtb infection include DAR-901 (Dartmouth, contains inactivated Mycobacterium obuense) 
and ID-93. Prevention of infection trials have the advantage of requiring relatively small 
sample sizes, but then require prevention of disease confirmation. Multiple other viral 
vectored, subunit and whole cell vaccine candidates are in earlier clinical trials, including a 
recombinant Mtb, MTBVAC (Biofabri), which has two mutations rendering the organism at 
least as safe as BCG in animal models. 
 
Among preclinical advances in 2018, a recombinant, attenuated cytomegalovirus (CMV) 
vaccine which expresses 6-9 Mtb antigens demonstrated the best protection against 
pulmonary Mtb challenge ever reported in non-human primates 12. This vector induces 
immunity in this animal model regardless of pre-existing CMV exposure, and may have a 
mechanism of action that is distinct from most other TB vaccination approaches, by inducing 
effector T cells that are widely distributed in all organs, including the lung, and which are 
continuously replenished due to ongoing antigen expression (most T cell targeted vaccines 
induce a long-lived central memory T cell response). Human testing of this candidate is 
under intense preparation.   
 
The TB vaccine field needs to move forward with a sense of urgency, and in a strategic, 
data-driven way. The current funding available for TB vaccines 13 will be insufficient to drive 
rapid progress, and therefore an increase and diversification of resources is required. Some 
of these resources should be used to increase clinical trial capacity, and to continue the 
discovery and advanced development of early pipeline candidates. 
 
A better understanding of protective immunity against TB is critical. Toward this goal, 
samples available from the two recent efficacy trials 3,4 could now be examined to identify 
mechanisms and correlates of protection, which, in turn, may contribute to accelerate clinical 
testing of candidates and guide future vaccine discovery. 
 
Models of vaccine use-case, in diverse geographical settings, should be developed to inform 
vaccine development strategies that could deliver most impact. Further modelling and 
health-economic research, into the public health impact and value of TB vaccines would 
support rational prioritisation of investments. Last, but no means least, we need to prepare 
for success; prompt implementation of successful vaccination strategies will be critical to 
help prevent the more than 4000 deaths due to TB each and every day.  
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